Squarepoint
SNDX icon

Squarepoint’s Syndax Pharmaceuticals SNDX Stock Holding History

Squarepoint’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$289K – 5467
2024
Q3 		$289K Buy
+15,000
New +$310K ﹤0.01% 3467

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Squarepoint's SNDX Position: Q2 2026 in Review

Squarepoint increased its Syndax Pharmaceuticals (SNDX) stake by 104% in Q2 2026, buying an estimated $3.93M and bringing the position to 370,317 shares worth $8.1M. The position accounts for 0.01% of the portfolio, ranked #1243.

Squarepoint first reported a position in SNDX in Q4 2017 and has held it in 17 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Squarepoint held 370,317 shares of Syndax Pharmaceuticals worth $8.1M as of Q2 2026.
  • Squarepoint bought 188,765 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.93M.
  • Syndax Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1243 holding.
  • Squarepoint first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.